SAN DIEGO and MELBOURNE, Australia—LENZ Therapeutics, Inc., (Nasdaq: LENZ) a pharmaceutical company focused on commercializing VIZZ (aceclidine ophthalmic solution) 1.44%, and Arrotex Pharmaceuticals Pty Ltd. have announced an exclusive licensing and commercialization agreement under which Arrotex will register and commercialize VIZZ eye drops for the treatment of presbyopia in Australia and New Zealand. The U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in July 2025, and VIZZ has been commercially available in the U.S. since October 2025.
Under the terms of the agreement, LENZ will receive an upfront payment and a significant profit share of gross margin from product sales, the companies stated. Arrotex, an Australian-owned and diversified pharmaceutical company offering an extensive range of prescription medicines across therapeutic areas, will hold exclusive commercialization rights for VIZZ for the treatment of presbyopia in Australia and New Zealand.
“We are pleased to expand our global commercial partnership network for VIZZ into Australia and New Zealand. Arrotex represents our fifth ex-US commercialization partnership for VIZZ, underscoring our commitment to broadening access to our transformative presbyopia therapy worldwide,” said Eef Schimmelpennink, president and CEO of LENZ Therapeutics. “Arrotex is a leading commercial partner in Australia and New Zealand, with an unmatched network of pharmacy partnerships and strong track record of bringing innovative branded medicines to patients. We look forward to working together to bring VIZZ to patients across the region.”
“We are thrilled to bring this innovative therapy to Australia and New Zealand for the treatment of presbyopia to the millions of adults frustrated with their near vision,” added Dennis Bastas, chairman and group CEO of DBG Health, the parent company of Arrotex Pharmaceuticals. “LENZ’s innovative treatment represents a first-to-market, once-daily solution that can provide visual freedom from reading glasses, offering the potential for greater visual independence and improved quality of life.”
In January, LENZ Therapeutics announced an exclusive distribution agreement for Lunatus Marketing & Consulting FZCO to register and commercialize VIZZ for the treatment of presbyopia in the Middle East. Earlier this month, the company announced that Everest Medicines (HKEX: 1952) had entered into an asset purchase agreement with Corxel Pharmaceuticals, under which Everest will acquire the rights to develop, manufacture and commercialize VIZZ (LNZ100) across Greater China, including mainland China, Hong Kong SAR, Macao SAR and Taiwan. A new drug application (NDA) for LNZ100 in China was submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China in September 2025, the company advised at the time, with approval anticipated in the first quarter of 2027.
